Patents by Inventor Christophe PEREZ

Christophe PEREZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160273003
    Abstract: A single chain homing endonuclease, comprising a first variant of I-CreI having the amino acid sequence of accession number pdb 1g9y and a second variant of I-CreI variant having the amino acid sequence of accession number pdb 1g9y in a single polypeptide.
    Type: Application
    Filed: March 24, 2016
    Publication date: September 22, 2016
    Inventors: Philippe DUCHATEAU, Christophe PEREZ, Sylvia BRUNEAU, Jean-Pierre CABANIOLS, Julianne SMITH, Agnes GOUBLE
  • Patent number: 9044492
    Abstract: A method for modulating double-strand break-induced mutagenesis at a genomic locus of interest in a cell, thereby giving new tools for genome engineering, including therapeutic applications and cell line engineering. A method for modulating double-strand break-induced mutagenesis, concerns the identification of effectors that modulate double-strand break-induced mutagenesis by use of interfering agents; these agents are capable of modulating double-strand break-induced mutagenesis through their respective direct or indirect actions on said effectors. Methods of using these effectors, interfering agents and derivatives, respectively, by introducing them into a cell in order to modulate and more particularly to increase double-strand break-induced mutagenesis. Specific derivatives of identified effectors and interfering agents, vectors encoding them, compositions and kits comprising such derivatives for modulating or increasing double-strand break-induced mutagenesis.
    Type: Grant
    Filed: February 6, 2012
    Date of Patent: June 2, 2015
    Assignee: CELLECTIS SA
    Inventors: Fabien Delacote, Philippe Duchateau, Christophe Perez-Michaut
  • Patent number: 8906607
    Abstract: The present invention concerns a method for modulating double-strand break-induced homologous recombination through the identification of effectors that modulate said double-strand break-induced homologous recombination by uses of interfering agents; these agents are capable of modulating double-strand break-induced homologous recombination through their respective actions on said effectors. The present invention also concerns the uses of these effectors and interfering agents and derivatives, respectively, by introducing them in an eukaryotic cell in order to modulate and more particularly to increase double-strand break-induced homologous recombination and gene targeting efficiency. The present invention also relates to specific derivatives of identified effectors and interfering agents, vectors encoding them, compositions and kits comprising such derivatives in order to modulate and more particularly to increase double-strand break-induced homologous recombination and gene targeting efficiency.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: December 9, 2014
    Assignee: Cellectis
    Inventors: Philippe Duchateau, Frédéric Paques, Christophe Perez-Michaut, Fabien Delacote
  • Publication number: 20140121115
    Abstract: New rare-cutting endonucleases, also called custom-made meganucleases, which recognize and cleave a specific nucleotide sequence, derived polynucleotide sequences, recombinant vector cell, animal, or plant comprising said polynucleotide sequences, process for producing said rare-cutting endonucleases and any use thereof, more particularly, for genetic engineering, antiviral therapy and gene therapy.
    Type: Application
    Filed: December 21, 2012
    Publication date: May 1, 2014
    Applicant: Cellectis
    Inventors: Sylvain Arnould, Sylvia Bruneau, Jean-Pierre Cabaniols, Patrick Chames, Andre Choulika, Phillipe Duchateau, Jean-Charles Epinat, Agnes Gouble, Emmanuel Lacroix, Frederic Paques, Christophe Perez-Michaut, Julianne Smith, Davie Sourdive
  • Publication number: 20140112904
    Abstract: A method for enhancing the cleavage activity of an I-CreI derived meganuclease, comprising the site-specific mutation of at least one amino acid residue which is selected in the group consisting of: the glycine at position 19, the phenylalanine at position 54, the phenylalanine at position 87, the serine at position 79, the valine at position 105 and the isoleucine at position 132 of I-CreI, and its application for the manufacturing of meganuclease cleaving a DNA target of interest, for use in genome therapy (treatment of genetic diseases) and genome engineering (making of transgenic animals, transgenic plants and recombinant cell lines).
    Type: Application
    Filed: June 6, 2008
    Publication date: April 24, 2014
    Applicant: Cellectis
    Inventors: Sylvestre Grizot, Agnes Gouble, Christophe Perez-Michaut
  • Publication number: 20140038239
    Abstract: An I-CreI variant, wherein one of the two I-CreI monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated respectively from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from the human beta globin gene. Use of said variant and derived products for the prevention and the treatment of pathological conditions caused by a mutation in the human beta globin gene (sickle cell disease, beta-thalassemia).
    Type: Application
    Filed: June 4, 2013
    Publication date: February 6, 2014
    Applicant: Cellectis
    Inventor: Christophe PEREZ-MICHAUT
  • Publication number: 20130190385
    Abstract: The present invention concerns a method for modulating double-strand break-induced homologous recombination through the identification of effectors that modulate said double-strand break-induced homologous recombination by uses of interfering agents; these agents are capable of modulating double-strand break-induced homologous recombination through their respective actions on said effectors. The present invention also concerns the uses of these effectors and interfering agents and derivatives, respectively, by introducing them in an eukaryotic cell in order to modulate and more particularly to increase double-strand break-induced homologous recombination and gene targeting efficiency. The present invention also relates to specific derivatives of identified effectors and interfering agents, vectors encoding them, compositions and kits comprising such derivatives in order to modulate and more particularly to increase double-strand break-induced homologous recombination and gene targeting efficiency.
    Type: Application
    Filed: April 30, 2010
    Publication date: July 25, 2013
    Applicant: Cellectis
    Inventors: Philippe Duchateau, Frédéric Paques, Christophe Perez-Michaut, Fabien Delacote
  • Publication number: 20130061341
    Abstract: An I-CreI variant which has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG (SEQ ID NO: 229) core domain situated from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from a xeroderma pigmentosum gene. Use of said variant and derived products for the prevention and the treatment of Xeroderma pigmentosum.
    Type: Application
    Filed: July 27, 2012
    Publication date: March 7, 2013
    Applicant: CELLECTIS S.A.
    Inventors: Sylvain Arnould, Christophe Perez-Michaut, Julianne Smith
  • Publication number: 20120322689
    Abstract: The present invention provides a method for detecting nucleic acid cleavage induced by a modified rare-cutting endonuclease derived from an initial rare-cutting endonuclease, said modified rare-cutting endonuclease being able to cleave a DNA target sequence, which may be different from the recognition and cleavage site of the initial rare-cutting endonuclease. In one embodiment of the invention expression of a marker gene is used as an indicator of target DNA cleavage.
    Type: Application
    Filed: June 15, 2012
    Publication date: December 20, 2012
    Applicant: CELLECTIS S.A.
    Inventors: Jean-Charles Epinat, Christophe Perez-Michaut, Frederic Paques
  • Publication number: 20120244131
    Abstract: A method for modulating double-strand break-induced mutagenesis at a genomic locus of interest in a cell, thereby giving new tools for genome engineering, including therapeutic applications and cell line engineering. A method for modulating double-strand break-induced mutagenesis, concerns the identification of effectors that modulate double-strand break-induced mutagenesis by use of interfering agents; these agents are capable of modulating double-strand break-induced mutagenesis through their respective direct or indirect actions on said effectors. Methods of using these effectors, interfering agents and derivatives, respectively, by introducing them into a cell in order to modulate and more particularly to increase double-strand break-induced mutagenesis. Specific derivatives of identified effectors and interfering agents, vectors encoding them, compositions and kits comprising such derivatives for modulating or increasing double-strand break-induced mutagenesis.
    Type: Application
    Filed: February 6, 2012
    Publication date: September 27, 2012
    Applicant: CELLECTIS SA
    Inventors: Fabien Delacote, Philippe Duchateau, Christophe Perez-Michaut
  • Publication number: 20120159659
    Abstract: New rare-cutting endonucleases, also called custom-made meganucleases, which recognize and cleave a specific nucleotide sequence, derived polynucleotide sequences, recombinant vector cell, animal, or plant comprising said polynucleotide sequences, process for producing said rare-cutting endonucleases and any use thereof, more particularly, for genetic engineering, antiviral therapy and gene therapy.
    Type: Application
    Filed: September 28, 2010
    Publication date: June 21, 2012
    Inventors: Sylvain Arnould, Sylvia Bruneau, Jean-Pierre Cabaniols, Patrick Chames, André Choulika, Philippe Duchateau, Jean-Pierre Epinat, Agnès Gouble, Emmanuel Lacroix, Frédéric Paques, Christophe Perez-Michaut, Julianne Smith, David Sourdive
  • Publication number: 20110287513
    Abstract: A single chain homing endonuclease, comprising a first variant of I-CreI having the amino acid sequence of accession number pdb 1g9y and a second variant of I-CreI variant having the amino acid sequence of accession number pdb 1g9y in a single polypeptide.
    Type: Application
    Filed: June 3, 2011
    Publication date: November 24, 2011
    Inventors: Sylvain Arnould, Sylvia Bruneau, Jean-Pierre Cabaniols, Patrick Chames, Andre Choulika, Philippe Duchateau, Jean-Charles Epinat, Agnes Gouble, Emmanuel Lacroix, Frederic Paques, Christophe Perez-Michaut, Julianne Smith, David Sourdive
  • Publication number: 20110151539
    Abstract: A single chain homing endonuclease, comprising a first variant of I-CreI having the amino acid sequence of accession number pdb 1g9y and a second variant of I-CreI variant having the amino acid sequence of accession number pdb 1g9y in a single polypeptide.
    Type: Application
    Filed: February 4, 2011
    Publication date: June 23, 2011
    Inventors: Sylvain Arnould, Sylvia Bruneau, Jean-Pierre Cabaniols, Patrick Chames, André Choulika, Philippe Duchateau, Jean-Charles Epinat, Agnes Gouble, Emmanuel Lacroix, Frederic Paques, Christophe Perez-Michaut, Julianne Smith, David Sourdive
  • Patent number: 7842489
    Abstract: A single chain homing endonuclease, comprising a first variant of I-CreI having the amino acid sequence of accession number pdb 1g9y (SEQ ID NO: 23 is residues 1-153 of pdb Ig9y) and a second variant of I-CreI variant having the amino acid sequence of accession number pdb 1g9y (SEQ ID NO: 23 is residues 1-153 of pdb Ig9y) in a single polypeptide.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: November 30, 2010
    Assignee: Cellectis
    Inventors: Sylvain Arnould, Sylvia Bruneau, Jean-Pierre Cabaniols, Patrick Chames, Andre Choulika, Philippe Duchateau, Jean-Charles Epinat, Agnes Gouble, Emmanuel Lacroix, Frederic Paques, Christophe Perez-Michaut, Julianne Smith, David Sourdive
  • Patent number: D939214
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: December 28, 2021
    Assignee: Dometic Sweden AB
    Inventors: Birk Söödi, Henrik Linder, Christophe Perez, Samuele Meda
  • Patent number: D968047
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: October 25, 2022
    Assignee: Dometic Sweden AB
    Inventors: Birk Söödi, Henrik Linder, Christophe Perez, Samuele Meda
  • Patent number: D981110
    Type: Grant
    Filed: December 13, 2021
    Date of Patent: March 21, 2023
    Assignee: Dometic Sweden AB
    Inventors: Birk Söödi, Henrik Linder, Christophe Perez, Samuele Meda
  • Patent number: D990087
    Type: Grant
    Filed: October 19, 2022
    Date of Patent: June 20, 2023
    Assignee: Dometic Sweden AB
    Inventors: Birk Söödi, Henrik Linder, Christophe Perez, Samuele Meda
  • Patent number: D991614
    Type: Grant
    Filed: October 19, 2022
    Date of Patent: July 4, 2023
    Assignee: Dometic Sweden AB
    Inventors: Birk Söödi, Henrik Linder, Christophe Perez, Samuele Meda
  • Patent number: D1014896
    Type: Grant
    Filed: October 19, 2022
    Date of Patent: February 13, 2024
    Assignee: Dometic Sweden AB
    Inventors: Birk Söödi, Henrik Linder, Christophe Perez, Samuele Meda